Introduction and Objective: Effective diabetes prevention strategies exist, yet sustained patient engagement in preventive pathways within routine primary care remains challenging. In 2022, Maccabi Healthcare Services implemented a prediabetes program in Nazareth and Nof HaGalil, two cities in Northern Israel, employing a shared decision-making model. Patients chose between physician-led care and physician care combined with […]
Read MoreAuthor: sugaradmin
1168-OR: Pancreas-Targeted Glucagon-Like Peptide 1 Gene Therapy Enhances β-Cell Function and Suppresses Cellular Stress in Preclinical Type 2 Diabetes Models
Introduction and Objective: β-cell dysfunction and loss drive type 2 diabetes (T2D) progression. Glucagon-like peptide-1 (GLP-1) receptor agonists improve β-cell function and health but are limited by discontinuation and glycemic rebound. We developed a single-dose adeno-associated virus gene therapy encoding human GLP-1 driven by an engineered insulin promoter (AAV.INS.GLP1) for durable, β-cell-specific, nutrient-responsive expression and […]
Read More1157-OR: Vasculogenic Fibroblasts In Vivo and Their Significance in the Rescue of Diabetic Ischemic Tissue
Introduction and Objective: Our recent work reported the identification of the adaptive vasculogenic fibroblast (VF), which can generate new blood vessels during tissue repair (Pal et al., Nat Commun, 2023). While these cells are physiologic and injury-inducible, they can also be therapeutically induced by inhibiting fibroblast miR-200b using tissue nanotransfection (TNT) technology (PMIDs: 28785092, 34837085, […]
Read More1176-OR: State-Level Variation in Medicaid Diabetes Drug Access, Use, and Adherence in the United States, 2016–2023
Introduction and Objective: State Medicaid programs differ widely in formulary design and prescribing practices for diabetes medications. Little is known about how formulary breadth translates into treatment initiation and sustained adherence. We assessed state-level variation in access, utilization, and adherence to major diabetes drug classes and examined alignment between formulary breadth and medication use.Methods: Using […]
Read More1206-OR: Mitochondrial Enzyme GLYAT Regulates Adipocyte Mitochondrial Function in Obesity
Introduction and Objective: GLYAT is a mitochondrial enzyme involved in medium-chain acyl-CoA metabolism, but its function in adipose tissue is unknown. We investigated the role of adipose GLYAT in obesity-associated metabolic dysfunction and its regulation of adipocyte mitochondrial function.Methods: Transcriptomic analysis was performed on paired subcutaneous and visceral adipose tissue samples from 236 participants (56 […]
Read More1191-OR: Progressive Failure of Brown Adipose Tissue Remodeling Drives Metabolic Aging
Introduction and Objective: Aging is the strongest risk factor for T2D, yet how age-dependent changes in energy-regulating tissues drive metabolic decline remains unclear. Brown adipose tissue (BAT) plays a role in adaptive thermogenesis and glucose metabolism, but whether aging alters BAT remodeling in a stage-dependent manner is unknown.Methods: We performed integrated metabolic phenotyping and single-cell […]
Read More2522-P: GPSM1 Controls Metabolism and Motor Function in Obesity via cAMP/PKA/YAP/TAZ-Mediated Mitochondrial Biogenesis
Introduction and Objective: The type 2 diabetes susceptibility gene GPSM1 is linked to impaired muscle function in patients, though its molecular mechanisms remain unknown. This study explores how GPSM1 regulates skeletal muscle metabolism and motor performance.Methods: Skeletal muscle-specific GPSM1 knockout (GPSM1MKO) mice were generated and maintained on either a standard chow or high-fat diet (HFD), […]
Read More2762-LB: Type 2 Diabetes Remission Rate and Change in Medication Burden after 12 Months of Intermittent Fasting
Introduction and Objective: Intermittent energy restriction (IER) and time-restricted eating (TRE) are two forms of intermittent fasting that may reduce diabetes medication needs in type 2 diabetes (T2D). However, head-to-head comparisons of IF approaches and trials using IF in T2D remain limited. We evaluated diabetes remission and pharmacologic de-intensification in a secondary analysis of a […]
Read More2232-P: Multiomics Integration Identifies Distinct Molecular Endotypes of Atypical Diabetes
Introduction and Objective: A convergence of dysregulated metabolic, polygenic and environmental factors drives the pathophysiology of diabetes mellitus. We performed unsupervised integration of transcriptomic and metabolomic data among participants in the Rare and Atypical Diabetes Network (RADIANT) to identify distinct endotypes of atypical diabetes.Methods: This cross-sectional, observational study included RADIANT participants meeting predefined atypical diabetes […]
Read More2521-P: Physical Inactivity Induced by Bed Rest Reduces Muscle but Not Hepatic or Adipose Tissue Insulin Sensitivity in Older Adults with or without Pre- or Type 2 Diabetes
Introduction and Objective: Older adults with pre-diabetes or type 2 diabetes experience hospitalization and bed rest more frequently than healthy older adults. However, the impact of physical inactivity induced by bed rest on insulin sensitivity in older adults with pre- or type 2 diabetes is unknown. To address this, we conducted a 10-day bed rest […]
Read More